Long‐term weight control study VII (weeks 0 to 210): Serum lipid changes

Michael Weintraub, Pavur R. Sundaresan, Barbara Schuster

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We analyzed serum total cholesterol, triglycerides, and lipoprotein profile changes occurring in the participants (N = 121) through 210 weeks of the study. On average, baseline lipid levels were within normal limits. The most consistent changes occurred in the high‐density lipoprotein cholesterol (HDL‐C), serum total cholesterol/HDL‐C ratios, and triglyceride levels. HDL‐C increased significantly (p < 0.01), compared with baseline, by 10% at week 34, 15% at week 54, 19% at week 104, and 27% at week 139. At week 210, 20 weeks after treatment had ended, HDL‐C was 15% higher than baseline. At weeks 34, 54, 104, and 139, the serum total cholesterol/HDL‐C ratio was significantly decreased, compared with baseline, by 9%, 19%, 17%, and 25%, respectively. At week 210, serum total cholesterol/HDL‐C ratio was 8% less than week 0. Compared with baseline, triglyceride levels decreased significantly by 21%, 31%, 29%, and 29% at weeks 34, 54, 104, and 139, respectively. At week 210, triglyceride levels were 16% below baseline. Total cholesterol levels and low‐density lipoprotein cholesterol (LDL‐C) showed less dramatic changes. Patterns of lipid and lipoprotein changes were qualitatively similar between men and women. However, greater decreases in serum total cholesterol, LDL‐C, and triglyceride levels were observed in participants with high (n = 10) compared with low (n = 10) baseline lipid levels. Cholesterol changes were not affected by anorexiant medications. However, triglyceride levels at week 34 were significantly (p < 0.025) less in the participants treated with anorexiants. Overall, participants in the long‐term weight control study had beneficial changes in their lipid profiles, thus decreasing their risk of coronary heart disease. Clinical Pharmacology and Therapeutics (1992) 51, 634–641; doi:

Original languageEnglish (US)
Pages (from-to)634-641
Number of pages8
JournalClinical Pharmacology & Therapeutics
Volume51
Issue number5
DOIs
StatePublished - Jan 1 1992

Fingerprint

Lipids
Weights and Measures
Serum
Cholesterol
Triglycerides
lipoprotein cholesterol
Clinical Pharmacology
Lipoproteins
Coronary Disease
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Long‐term weight control study VII (weeks 0 to 210) : Serum lipid changes. / Weintraub, Michael; Sundaresan, Pavur R.; Schuster, Barbara.

In: Clinical Pharmacology & Therapeutics, Vol. 51, No. 5, 01.01.1992, p. 634-641.

Research output: Contribution to journalArticle

Weintraub, Michael ; Sundaresan, Pavur R. ; Schuster, Barbara. / Long‐term weight control study VII (weeks 0 to 210) : Serum lipid changes. In: Clinical Pharmacology & Therapeutics. 1992 ; Vol. 51, No. 5. pp. 634-641.
@article{28d480e0a81e470e964e73d0556515b7,
title = "Long‐term weight control study VII (weeks 0 to 210): Serum lipid changes",
abstract = "We analyzed serum total cholesterol, triglycerides, and lipoprotein profile changes occurring in the participants (N = 121) through 210 weeks of the study. On average, baseline lipid levels were within normal limits. The most consistent changes occurred in the high‐density lipoprotein cholesterol (HDL‐C), serum total cholesterol/HDL‐C ratios, and triglyceride levels. HDL‐C increased significantly (p < 0.01), compared with baseline, by 10{\%} at week 34, 15{\%} at week 54, 19{\%} at week 104, and 27{\%} at week 139. At week 210, 20 weeks after treatment had ended, HDL‐C was 15{\%} higher than baseline. At weeks 34, 54, 104, and 139, the serum total cholesterol/HDL‐C ratio was significantly decreased, compared with baseline, by 9{\%}, 19{\%}, 17{\%}, and 25{\%}, respectively. At week 210, serum total cholesterol/HDL‐C ratio was 8{\%} less than week 0. Compared with baseline, triglyceride levels decreased significantly by 21{\%}, 31{\%}, 29{\%}, and 29{\%} at weeks 34, 54, 104, and 139, respectively. At week 210, triglyceride levels were 16{\%} below baseline. Total cholesterol levels and low‐density lipoprotein cholesterol (LDL‐C) showed less dramatic changes. Patterns of lipid and lipoprotein changes were qualitatively similar between men and women. However, greater decreases in serum total cholesterol, LDL‐C, and triglyceride levels were observed in participants with high (n = 10) compared with low (n = 10) baseline lipid levels. Cholesterol changes were not affected by anorexiant medications. However, triglyceride levels at week 34 were significantly (p < 0.025) less in the participants treated with anorexiants. Overall, participants in the long‐term weight control study had beneficial changes in their lipid profiles, thus decreasing their risk of coronary heart disease. Clinical Pharmacology and Therapeutics (1992) 51, 634–641; doi:",
author = "Michael Weintraub and Sundaresan, {Pavur R.} and Barbara Schuster",
year = "1992",
month = "1",
day = "1",
doi = "10.1038/clpt.1992.75",
language = "English (US)",
volume = "51",
pages = "634--641",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Long‐term weight control study VII (weeks 0 to 210)

T2 - Serum lipid changes

AU - Weintraub, Michael

AU - Sundaresan, Pavur R.

AU - Schuster, Barbara

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We analyzed serum total cholesterol, triglycerides, and lipoprotein profile changes occurring in the participants (N = 121) through 210 weeks of the study. On average, baseline lipid levels were within normal limits. The most consistent changes occurred in the high‐density lipoprotein cholesterol (HDL‐C), serum total cholesterol/HDL‐C ratios, and triglyceride levels. HDL‐C increased significantly (p < 0.01), compared with baseline, by 10% at week 34, 15% at week 54, 19% at week 104, and 27% at week 139. At week 210, 20 weeks after treatment had ended, HDL‐C was 15% higher than baseline. At weeks 34, 54, 104, and 139, the serum total cholesterol/HDL‐C ratio was significantly decreased, compared with baseline, by 9%, 19%, 17%, and 25%, respectively. At week 210, serum total cholesterol/HDL‐C ratio was 8% less than week 0. Compared with baseline, triglyceride levels decreased significantly by 21%, 31%, 29%, and 29% at weeks 34, 54, 104, and 139, respectively. At week 210, triglyceride levels were 16% below baseline. Total cholesterol levels and low‐density lipoprotein cholesterol (LDL‐C) showed less dramatic changes. Patterns of lipid and lipoprotein changes were qualitatively similar between men and women. However, greater decreases in serum total cholesterol, LDL‐C, and triglyceride levels were observed in participants with high (n = 10) compared with low (n = 10) baseline lipid levels. Cholesterol changes were not affected by anorexiant medications. However, triglyceride levels at week 34 were significantly (p < 0.025) less in the participants treated with anorexiants. Overall, participants in the long‐term weight control study had beneficial changes in their lipid profiles, thus decreasing their risk of coronary heart disease. Clinical Pharmacology and Therapeutics (1992) 51, 634–641; doi:

AB - We analyzed serum total cholesterol, triglycerides, and lipoprotein profile changes occurring in the participants (N = 121) through 210 weeks of the study. On average, baseline lipid levels were within normal limits. The most consistent changes occurred in the high‐density lipoprotein cholesterol (HDL‐C), serum total cholesterol/HDL‐C ratios, and triglyceride levels. HDL‐C increased significantly (p < 0.01), compared with baseline, by 10% at week 34, 15% at week 54, 19% at week 104, and 27% at week 139. At week 210, 20 weeks after treatment had ended, HDL‐C was 15% higher than baseline. At weeks 34, 54, 104, and 139, the serum total cholesterol/HDL‐C ratio was significantly decreased, compared with baseline, by 9%, 19%, 17%, and 25%, respectively. At week 210, serum total cholesterol/HDL‐C ratio was 8% less than week 0. Compared with baseline, triglyceride levels decreased significantly by 21%, 31%, 29%, and 29% at weeks 34, 54, 104, and 139, respectively. At week 210, triglyceride levels were 16% below baseline. Total cholesterol levels and low‐density lipoprotein cholesterol (LDL‐C) showed less dramatic changes. Patterns of lipid and lipoprotein changes were qualitatively similar between men and women. However, greater decreases in serum total cholesterol, LDL‐C, and triglyceride levels were observed in participants with high (n = 10) compared with low (n = 10) baseline lipid levels. Cholesterol changes were not affected by anorexiant medications. However, triglyceride levels at week 34 were significantly (p < 0.025) less in the participants treated with anorexiants. Overall, participants in the long‐term weight control study had beneficial changes in their lipid profiles, thus decreasing their risk of coronary heart disease. Clinical Pharmacology and Therapeutics (1992) 51, 634–641; doi:

UR - http://www.scopus.com/inward/record.url?scp=0026566183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026566183&partnerID=8YFLogxK

U2 - 10.1038/clpt.1992.75

DO - 10.1038/clpt.1992.75

M3 - Article

C2 - 1587078

AN - SCOPUS:0026566183

VL - 51

SP - 634

EP - 641

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -